
This content was machine translated.
About RNATICS GmbH
RNATICS develops medicines based on short nucleic acid molecules, so-called oligonucleotides, that target disease-causing RNAs in tissue-resident macrophages. This novel delivery mechanism enables access to organs that have previously been inaccessible for nucleic acid therapies, opening up significant therapeutic potential in many diseases. We plan to start the first clinical trial (Phase I) of our lead candidate, RCS-21, for the treatment of fibrotic lung disease following viral infections (e.g. COVID-19) in spring 2024.
More like this
Discover more articles, startups, and events from the ecosystem

Ecosystem
Munich Startup Recap 43/26
25.10.26
2 Min.

Ecosystem
GoCircular Munich: A Map for Munich’s Circular Economy
23.10.26
3 Min.

Interviews
Ahron: The Future of HR? Fewer Clicks, More People
23.10.26
4 Min.

Conference
beyond economy Festival
October 28, 2026
08:00 AM – 06:00 PM
House of Communication, Munich

Online Event
Startup Fails No One Tells You About (Until It’s Too Late)
October 28, 2026
11:00 AM – 12:00 PM
Online